Trastuzumab deruxtecan RNA Pull Down with C-terminal 8*His MVPPPENVRMNSVNFKNILQWESPAFAKGNLTFTAQYLSYRIFQDKCMNTTLTECDFSSLSKYGDHTLRVRAEFADEHSDWVNITFCPVDDTIIGPPGMQVEVLADSLHMRFLAPKIENEYETWTMKNVYNSWTYNVQYWKNGTDEKFQITPQYDFEVLRNLEPWTTYCVQVRGFLPDRNKAGEWSEPVCEQTTHDETVPSGGGSHHHHHHHH

with C-terminal 8*His MVPPPENVRMNSVNFKNILQWESPAFAKGNLTFTAQYLSYRIFQDKCMNTTLTECDFSSLSKYGDHTLRVRAEFADEHSDWVNITFCPVDDTIIGPPGMQVEVLADSLHMRFLAPKIENEYETWTMKNVYNSWTYNVQYWKNGTDEKFQITPQYDFEVLRNLEPWTTYCVQVRGFLPDRNKAGEWSEPVCEQTTHDETVPSGGGSHHHHHHHH

Recovery Range: 80-102%

and discarded with PBS

Brome Mosaic virus and many more present in cultured cells and fixed paraffin embedded histological samples

Trastuzumab deruxtecan RNA Pull Down with C-terminal 8*His MVPPPENVRMNSVNFKNILQWESPAFAKGNLTFTAQYLSYRIFQDKCMNTTLTECDFSSLSKYGDHTLRVRAEFADEHSDWVNITFCPVDDTIIGPPGMQVEVLADSLHMRFLAPKIENEYETWTMKNVYNSWTYNVQYWKNGTDEKFQITPQYDFEVLRNLEPWTTYCVQVRGFLPDRNKAGEWSEPVCEQTTHDETVPSGGGSHHHHHHHHProduct Specification Antibody Type ADC Concentration 1 mg ml Endotoxin <1EU mg Physical Appearance Liquid Storage Buffer Reconstitute the Trastuzumab deruxtecan using 0. 9% Sodium Chloride Injection Stability & Storage 2 to 8 C for 2 weeks under sterile conditions; 20 C for 3 months under sterile conditions; 80 C for 24 months under sterile conditions. Please avoid repeated freeze thaw cycles. Background Trastuzumab deruxtecan (DS 8201a) is an anti